Lyell Immunopharma, Inc.
LYEL
$13.95
$0.211.53%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -55.00% | -52.31% | -40.98% | -34.92% | 11.11% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -55.00% | -52.31% | -40.98% | -34.92% | 11.11% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -55.00% | -52.31% | -40.98% | -34.92% | 11.11% |
| SG&A Expenses | -19.33% | -22.72% | -13.27% | -3.25% | -7.90% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -31.15% | -37.40% | -35.83% | -51.09% | -45.32% |
| Total Operating Expenses | -10.03% | -15.32% | -9.73% | -8.50% | -6.07% |
| Operating Income | 10.02% | 15.31% | 9.73% | 8.49% | 6.07% |
| Income Before Tax | 25.02% | 26.34% | 19.98% | -59.65% | -57.61% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 25.02% | 26.34% | 19.98% | -59.65% | -57.61% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 25.02% | 26.34% | 19.98% | -59.65% | -57.61% |
| EBIT | 10.02% | 15.31% | 9.73% | 8.49% | 6.07% |
| EBITDA | 7.39% | 12.91% | 6.63% | 6.55% | 4.81% |
| EPS Basic | 49.16% | 46.64% | 39.69% | -38.91% | -42.30% |
| Normalized Basic EPS | 34.69% | 34.20% | 20.38% | 19.02% | 13.32% |
| EPS Diluted | 49.16% | 46.64% | 39.69% | -38.91% | -42.30% |
| Normalized Diluted EPS | 34.69% | 34.20% | 20.38% | 19.02% | 13.32% |
| Average Basic Shares Outstanding | 49.08% | 38.86% | 30.66% | 21.35% | 11.19% |
| Average Diluted Shares Outstanding | 49.08% | 38.86% | 30.66% | 21.35% | 11.19% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |